Santa Ana Bio is a biotechnology company developing a pipeline of innovative therapeutics and leveraging its multi-omics platform to unlock the full potential of precisions medicines. Santa Ana's platform, based on transcriptomics and proteomics, addresses the limitations of today's commercial therapeutics. The goal is to expand the reach of precision medicines to different cell types and pathways, to benefit more patients with autoimmune and inflammatory diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/13/24 | $168,000,000 | Series A and B |
Access Biotechnology Andreessen Horowitz Bio+Health GV  Life Sciences Innovation Fund RTW Investments Versant Ventures | undisclosed |
